On January 6, 2026, AngioDynamics raised its fiscal 2026 net sales guidance to US$312 million–US$314 million and reported narrower losses on higher quarterly sales, while also disclosing that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback